MedTrace Logo

Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

NCT02843399 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15498

Last updated 2017-12-15

No results posted yet for this study

Summary

Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.

Conditions

  • Diabetes Mellitus Type 2

Sponsors & Collaborators

  • Truven health

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Eric T. Wittbrodt, PharmD, MPH · AstraZeneca

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-15
Primary Completion
2016-12-15
Completion
2016-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02843399 on ClinicalTrials.gov